These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 4151750)
21. Tardive dyskinesia: side effect or not? Curran JP Am J Psychiatry; 1973 Apr; 130(4):406-10. PubMed ID: 4144163 [No Abstract] [Full Text] [Related]
22. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
23. Antipsychotic drugs--an update. Charalampous KD; Keepers GA J Okla State Med Assoc; 1978 Jan; 71(1):6-9. PubMed ID: 23420 [No Abstract] [Full Text] [Related]
24. The costs of drugs for schizophrenia. Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146 [No Abstract] [Full Text] [Related]
25. General evaluation of pipotiazine palmitate (19.552 R.P.) in hospitalized schizophrenic patients. Gerlach J; Nyeborg O; Prieto R Acta Psychiatr Scand Suppl; 1973; 241():69-74. PubMed ID: 4147513 [No Abstract] [Full Text] [Related]
26. [Aspects of neuroleptic depot therapy with special consideration of clinical experiences with the preoral depot preparation Penfluridol (R 16 341-Jannsen)]. Bruck J; Guss H Int Pharmacopsychiatry; 1974; 9(3):152-65. PubMed ID: 4154320 [No Abstract] [Full Text] [Related]
27. Monthly intermittent chemotherapy of chronic schizophrenic outpatients with pipothiazine palmitate. Laurent JS; Carle R; Dumais B; Domingue D Can Psychiatr Assoc J; 1974 Dec; 19(6):583-91. PubMed ID: 4155349 [No Abstract] [Full Text] [Related]
31. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. Gerlach J J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196 [TBL] [Abstract][Full Text] [Related]
32. Lessons from each drug trial. Marder SR Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457 [No Abstract] [Full Text] [Related]
33. Anticholinergics to treat antipsychotic-induced extrapyramidal symptoms: Time to avoid this practice. Koola MM Asian J Psychiatr; 2018 Jan; 31():100-101. PubMed ID: 29454175 [No Abstract] [Full Text] [Related]
34. Effect of phenothiazines on central cholinergic activity. Van Woert MH; Sethy VH; Ambani LM Adv Biochem Psychopharmacol; 1974; 9(0):707-15. PubMed ID: 4151771 [No Abstract] [Full Text] [Related]
35. A preliminary evaluation of pipothiazine palmitate in schizophrenia. Imlah NW; Murphy KP Curr Med Res Opin; 1975; 3(3):169-74. PubMed ID: 238791 [TBL] [Abstract][Full Text] [Related]
36. Medical and legal implications of side effects from neuroleptic drugs. A round-table discussion. Cancro R; Davis JM; Klawans H; Tancredi L J Clin Psychiatry; 1981 Feb; 42(2):78-82. PubMed ID: 6109720 [TBL] [Abstract][Full Text] [Related]
37. Cannabis-induced extrapyramidalism in a patient on neuroleptic treatment. Rejón Altable C; Rodríguez Urrutia A; Carrión Martínez MI J Clin Psychopharmacol; 2005 Feb; 25(1):91-2. PubMed ID: 15643106 [No Abstract] [Full Text] [Related]